Lucent

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lucent

Property Description
Active ingredient Calcitriol (1alpha,25-dihydroxycholecalciferol)
Form Oral Capsule, Oral Solution, Injectable Solution
Pharmacological class Vitamin D Analog / Calcitrophic Hormone
General purpose Mineral homeostasis and bone health support
Origin Synthetic (chemically manufactured)

What is Calcitriol? Defining Lucent's Active Ingredient and Class

Lucent is a pharmaceutical preparation whose single active ingredient is Calcitriol, the most biologically potent and active form of Vitamin D in the body. Calcitriol is chemically known as 1alpha,25-dihydroxycholecalciferol and is classified as a Vitamin D Analog and a calcitrophic hormone. This distinction is clinically significant; unlike common dietary Vitamin D forms, Calcitriol is the ready-to-use hormone, having already undergone the final activation steps that usually occur in the body. Pharmacological studies consistently recognize that this direct active form is critical for individuals with impaired kidney function who cannot activate standard Vitamin D effectively.


Lucent: Origin, Composition, and Pharmaceutical Forms

Lucent is a single-ingredient, synthetic compound, manufactured to be structurally identical to the naturally occurring active human hormone. Its synthetic origin ensures consistent purity and stable therapeutic activity. The medication is offered in several presentations, including the oral capsule and oral solution. For patients requiring direct systemic delivery, such as those undergoing dialysis, an injectable solution for intravenous administration is available. This capability for intravenous delivery is a key differentiating factor, making it suitable for acute or severe deficiency management where oral absorption is not feasible.


What is the General Purpose of Calcitriol?

The general purpose of Calcitriol is to support mineral homeostasis by acting as the main regulator of calcium and phosphate metabolism. Its function is to enhance the body's absorption of dietary calcium from the gastrointestinal tract and to help maintain appropriate calcium levels in the blood. The medical community widely acknowledges the necessity of Calcitriol in regulating serum calcium, which is vital for preserving the structural health of bone tissue. By performing these fundamental regulatory actions, Lucent helps correct critical mineral deficiencies and stabilizes imbalances, typically in the context of chronic kidney conditions.

Regulatory References

  1. Calcitriol - StatPearls - NCBI Bookshelf

What side effects are possible with Lucent?

Possible Side Effects and Safety Information

The official safety profile of Calcitriol (Lucent) is defined by its core action on mineral metabolism, with the primary concern being the development of elevated calcium levels. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOC) based on regulatory documents.


Official Adverse Reaction Categories

Classification Examples of Officially Listed Reactions
Common Hypercalcaemia (high blood calcium), Hypercalciuria (high calcium in urine)
Less Common Headache, Nausea, Vomiting, Constipation, Weakness, Somnolence, Rash

Serious Adverse Reactions and Safety Patterns

Chronic, uncontrolled Hypercalcaemia is associated with the most significant long-term safety concerns, including generalized vascular and soft-tissue calcification (ectopic calcification) and potential renal impairment, as documented in official prescribing information. The earliest signs of hypercalcaemia, such as headache, weakness, and dry mouth, are often associated with the initial phase of treatment or following a dose change.


Safety Restrictions

Regulatory documents state that the medication is contraindicated in patients with pre-existing Hypercalcaemia or documented evidence of Vitamin D toxicity. For patients with renal impairment, the safety profile requires strict maintenance of the serum calcium times phosphate product to minimize the risk of serious soft tissue calcification, establishing a fundamental safety limitation for its use.

Overdose and Emergency Response

Lucent Overdose and when to seek help

Documented Overdose Presentations

The official overdose profile is defined by Progressive Hypercalcemia Syndrome, which results from acute or chronic overexposure to the active ingredient. Early documented manifestations include general symptoms such as weakness, headache, nausea, vomiting, dry mouth, muscle pain, and metallic taste. If toxicity progresses, late manifestations such as polyuria, polydipsia, weight loss, and hypertension may be observed. The affected physiological systems include the renal system (elevated BUN, nephrocalcinosis), the cardiovascular system (potential cardiac arrhythmias and vascular calcification), and the neurological system (apathy, somnolence).


Emergency Response and Required Medical Attention

Regulators classify progressive hypercalcemia as a condition that may be so severe as to require emergency attention. Treatment must be stopped immediately upon evidence of hypercalcemia, and all calcium and vitamin D supplements must be withheld, as they contribute to the overdosage profile. The risk of generalized vascular calcification and potentially life-threatening cardiac arrhythmias in vulnerable patients defines the need for urgent medical evaluation. The overdose risk is specifically heightened in immobilized patients and those concurrently taking Digitalis due to the associated arrhythmia risk.

Therapeutic Uses of Lucent

What Lucentis Treats: Main Uses and Benefits

Lucentis (ranibizumab) is an established medication for managing symptoms that interfere with daily functioning in the context of certain retinal conditions. Its use is relevant for conditions presenting with systemic or localized discomfort and inflammation. The treatment is relevant for conditions involving episodic or fluctuating manifestations such as Neovascular (Wet) Age-Related Macular Degeneration (AMD).

The medication is used when symptoms intensify and supportive relief is needed, particularly in clinical settings involving acute or unstable symptom patterns. It plays a role in managing macular edema secondary to retinal vein occlusion (RVO) and Diabetic Macular Edema (DME). The treatment is also relevant in contexts involving heightened systemic burden such as Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).

The treatment provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms are more noticeable. This supportive approach helps patients cope more steadily with symptom fluctuations.

“The treatment is applied in addressing conditions where functional stability becomes affected.”

Quick Fact: Relief for symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Lucent (Calcitriol) is officially indicated for use in adult patients with Chronic Renal Failure (CKD), including those undergoing chronic dialysis and those with moderate to severe CKD not yet requiring dialysis. It is also approved for patients with various forms of hypoparathyroidism (e.g., post-surgical, idiopathic).

Populations for whom use is contraindicated: The medicine must not be used in patients with pre-existing hypercalcemia (abnormally high blood calcium levels) or any evidence of Vitamin D toxicity. Use is also prohibited in patients with known hypersensitivity to calcitriol or any related Vitamin D derivative, as well as those already taking other Vitamin D products.

Age and Condition Restrictions

Age-Related Eligibility Rules: The safety and effectiveness of certain oral capsule formulations in pediatric patients (under 18 years) have not been sufficiently investigated; therefore, use is not recommended for these specific forms. Older adults may be treated with caution, as specific dosage modifications are not required solely based on age.

Pregnancy and Lactation Eligibility Status: Lucent is classified as Pregnancy Category C. Use during pregnancy is conditional and requires close monitoring. Use in breastfeeding women is generally not recommended due to the unknown risk of drug transfer to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lucent (Calcitriol) is defined by its role in regulating mineral homeostasis, leading to specific restrictions documented in official regulatory labeling.

Formal Contraindications and Restrictions

Co-administration with any other Vitamin D products or derivatives is formally contraindicated because of the additive risk of severe hypercalcemia (excessive calcium levels). A specific restriction applies to patients with chronic renal failure or those on dialysis: the use of magnesium-containing antacids or other magnesium preparations is contraindicated due to the risk of hypermagnesemia in this population. Strict observation of dietary constraints is also mandated, particularly avoiding uncontrolled intake of calcium- or phosphate-containing preparations or supplements.

Documented Pharmacodynamic and Exposure Interactions

Medicines that reinforce Calcitriol's effect on calcium require caution. Thiazide diuretics increase the risk of hypercalcemia by reducing urinary calcium excretion. Co-administration with Digitalis preparations requires close monitoring, as Calcitriol-induced hypercalcemia may precipitate cardiac arrhythmias. An antagonistic relationship exists with corticosteroids, which inhibit calcium absorption. On a pharmacokinetic basis, bile acid sequestrants like Cholestyramine may reduce the intestinal absorption of Calcitriol, potentially leading to decreased drug exposure. The label also notes enzyme induction by certain anticonvulsants (e.g., Phenytoin) that affects Vitamin D precursors. The regulatory profile mandates the immediate cessation of Calcitriol if hypercalcemia develops.

Mechanism of Action

Targeted Action: Interleukin-23 Neutralization

Lucent is a specialized antibody that functions as a selective inhibitor by binding with high affinity to the p19 subunit of the cytokine Interleukin-23 (IL-23), a key messenger protein in the immune system. This targeted binding physically prevents the IL-23 molecule from interacting with its receptor on immune cells, thereby neutralizing its biological signaling activity .


Modulating the Chronic Inflammatory Cascade

This neutralization disrupts the downstream signaling of the IL-23/T-helper 17 (Th17) axis, a central pathway driving chronic tissue responses. This mechanistic action results in a decrease in the overall inflammatory response within affected tissues by reducing the release of pro-inflammatory mediators, such as Interleukin-17 (IL-17).


Resulting Physiological Stabilization

The reduction in chronic immune activity lowers the sustained pathological burden on the tissue. This mechanism modifies the tissue environment, leading to a physiological state characterized by reduced inflammatory signaling and a shift toward structural maintenance.

Dosage and Administration Information

How to Use Lucent (Calcitriol) — Official Administration Guidelines

Administration of Lucent is governed by precise instructions covering route, dosage, and monitoring. The active ingredient, Calcitriol, is supplied in forms suitable for Oral (capsules and solution), Intravenous (IV) injection, and Topical (ointment) routes.


Administration Scope

Route of administration Oral, Intravenous (IV), and Topical.
Dosing schedule Adult Oral Initial doses are typically 0.25 mcg daily or every other day, with subsequent titration at 4 to 8 week intervals. IV Initial doses are 1 to 2 mcg (0.02 mu g/kg) administered three times weekly.
Timing in relation to meals (if applicable) Oral forms may be taken with or without food.
Preparation requirements (if applicable) Oral capsules should be swallowed with a little water.
Age-group administration rules Pediatric dosing is calculated based on age and body weight; dosage for older adults typically begins at the low end of the adult range.
Missed-dose rules Specific guidance on a missed dose varies by product label, emphasizing adherence to the prescribed daily or weekly schedule.
Special procedural conditions Effective therapy requires concomitant adequate daily calcium intake (e.g., 600 to 1300 mg). IV administration is a rapid bolus injection typically given at the end of a hemodialysis session. Topical use must be without an occlusive dressing.

Instruction Classifications (high-level)

Administration method type Oral, Intravenous, Topical.
Frequency pattern Daily, Every Other Day, and Three Times Weekly (IV).
Guidelines basis Prescribing Information and Summary of Product Characteristics.
Use-context constraints Administration is conditional on concurrent adequate calcium intake and close laboratory monitoring.

Resulting Procedural Structure

Official step sequence:

  • The appropriate route and formulation are determined based on patient context.
  • The labeled starting dose is administered, necessitating concurrent daily calcium intake.
  • Biochemical markers are checked frequently (e.g., twice weekly) during the initial phase.
  • The dose is titrated (adjusted) over intervals of weeks based on monitoring results to achieve the maintenance regimen.
  • Treatment must be temporarily stopped if specific laboratory parameters exceed defined limits.

Connection to the overall use protocol: The official use protocol for Lucent is structured around dynamic dose titration and specific delivery rules, defining how the medicine is to be administered in precise relation to patient-specific laboratory results. The instructions establish a framework for controlled dosing across multiple approved routes and require continuous monitoring to ensure adherence to defined parameters for administration.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Lucent

This section provides an overview of the clinical research that has evaluated Lucent (Calcitriol) for its approved uses. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The evidence highlights what is known—and what is still uncertain—about this agent.


Evidence for Mineral Balance in Chronic Kidney Disease (CKD) on Dialysis

The research base includes Randomized Controlled Trials (RCTs) and various long-term observational studies that have evaluated the outcomes related to serum calcium and Parathyroid Hormone (PTH) concentrations in adult patients undergoing chronic dialysis. Findings describe patterns of changes in serum PTH concentrations in the observed populations. Data describe patterns of serum calcium concentrations relative to predefined targets. However, long-term outcomes are not fully established. While studies describe patterns of change in these markers, it remains unclear if these changes correlate directly with verifiable observable clinical differences in hard clinical outcomes for patients, such as a reduced incidence of bone fractures.

Evidence for Secondary Hyperparathyroidism in Non-Dialysis CKD

Lucent was studied for conditions characterized by functional imbalance in adult patients with earlier stages of CKD (Stages 3, 4, and 5) and elevated PTH levels. These studies typically consisted of intermediate-term RCTs. Findings indicate that a portion of the patient cohorts showed lower measured serum PTH levels during the study period. Studies also monitored concurrent changes; for example, studies reported the co-occurrence of increased serum calcium and phosphate levels, which are observed in some research alongside the changes in PTH. The clinical relevance of these concurrent elevations remains an area where certainty is low.

Evidence for Calcium Stabilization in Hypoparathyroidism

Lucent was studied for its role in the balance of serum calcium concentrations in patients—including adults and children—diagnosed with confirmed Hypoparathyroidism. Research highlights changes measured during the study period, describing the patterns of stabilization in serum calcium concentrations across the majority of the observed populations. However, studies tracking long-term use frequently reported concurrent increased levels of calcium in the urine, which was associated with the agent's use. The long-term effects of this finding on renal health and the risk of kidney stone formation are not fully established, and data are still emerging.


What Research Currently Indicates is Still Uncertain

The certainty remains low regarding the correlation between the reported changes in biomarkers (like PTH and calcium levels) and observable clinical differences in major clinical events such as bone fractures or improved survival. Comparative evidence against other treatments, such as newer Vitamin D receptor activators, for long-term patient outcomes is often lacking.

Key Studies & References

  1. Calcitriol - StatPearls - NCBI Bookshelf (Regulatory and CKD/Hypopara Indication Overview)
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
  3. Secondary Hyperparathyroidism in Non-dialysis Chronic Kidney Disease (Review discussing active vitamin D use and risks of hypercalcemia/hyperphosphatemia)

Frequently Asked Questions (FAQ)

Common questions about Lucent (FAQ)


Q: How quickly does Lucent typically start working?

According to the official product information, the initial pharmacologic activity of a dose is described as lasting about 3 to 5 days in the body. The injectable form, used in contexts like dialysis, is noted to be available in the bloodstream quickly after administration.


Q: How long do the described effects of Lucent last?

Regulatory documents note that the main pharmacologic activity of a single administered dose of the active ingredient, calcitriol, lasts about 3 to 5 days. This duration influences the required frequency of subsequent doses.


Q: What happens if I forget to take Lucent sometimes?

Official consumer information provides guidance for adherence. Regulatory guidance suggests taking the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, official guidance indicates skipping the missed dose and not taking extra medicine to make up the difference.


Q: Are there any specific foods or drinks that are noted to interact with Lucent?

The official labeling notes that treatment may require careful adjustment of the intake of foods containing calcium, phosphate, and vitamin D. Some regulatory-based information also suggests that grapefruit and grapefruit juice consumption may alter the medicine's blood levels.


Q: Can Lucent be used by older adults (e.g., people over 65)?

Official documents describe that dose selection for an older adult should be cautious, typically starting at the low end of the dosage range. Specific dose modifications are not required solely based on age, but close medical oversight is generally part of the regimen.


Q: Can Lucent cause any changes to sleep patterns?

Official safety profiles list somnolence, which means drowsiness or feeling sleepy, as a less common adverse reaction. This is an effect on the central nervous system that may be noted during treatment.


Q: What is the official storage information for Lucent?

Official product information specifies that oral capsules require storage at controlled room temperature (20 C to 25 C), protected from moisture and excessive heat, and kept in the original, tightly closed container. The injectable solution is specifically labeled with the constraint: Do not freeze.


Q: Is it necessary to take Lucent at the exact same time every day?

While the label does not use the phrase 'exact same time,' regulatory guidance underscores the importance of adherence to the prescribed daily or weekly schedule. Consistent timing helps ensure proper maintenance of mineral balance and supports accurate laboratory monitoring results.


Q: Why do some people refer to Lucent as a 'specialist' medication?

Lucent (Calcitriol) is described in authoritative sources as the most biologically active form of Vitamin D in the body. Its use is formally indicated for specialized conditions like Chronic Renal Failure (CKD) and Hypoparathyroidism, which typically require specialist oversight.


Q: Does Lucent require long-term use, or is it for short periods?

The medical literature includes long-term observational studies that have tracked patients using the drug for several years. The duration of use is contingent on the specific condition it is prescribed for and the ongoing clinical need for mineral balance support.


Q: Can Lucent be taken with multivitamins or mineral supplements?

Co-administration with other Vitamin D products or derivatives is formally contraindicated. Regulatory documents indicate the need for caution regarding the uncontrolled intake of supplements containing calcium or phosphate, as multivitamins often contain these components.


Q: Does Lucent affect the ability to drive or operate machinery?

The consumer information for this medicine states that the ability to drive a car or operate machinery should not normally be affected by Lucent. However, this may be contingent on any adverse reactions that occur during treatment.


Q: How are research trials for Lucent described in high-level summaries?

The research base includes Randomized Controlled Trials (RCTs) and various long-term observational studies that evaluated outcomes related to mineral balance in approved patient populations, such as those with Chronic Kidney Disease.


Q: Does the efficacy of Lucent rely on specific lifestyle factors?

Official instructions note that effective therapy requires a concomitant adequate daily calcium intake in the form of diet or supplements. This daily intake is a necessary condition for the medicine to work as intended.


Q: Are there specific laboratory tests mentioned in official sources for people using Lucent?

Yes, regulatory documents describe the necessity of frequent laboratory monitoring. During the initial phase and dose adjustment, serum levels of calcium and phosphorus are often determined at least twice weekly. Monitoring of Parathyroid Hormone (PTH) concentrations is also typically required.


Q: What does it mean that Lucent is a 'prescription-only' medicine?

The designation means the medicine can only be obtained with a valid prescription from a healthcare professional. This classification is related to the drug's potent action on mineral metabolism and the necessity for frequent, specialized laboratory monitoring.


Q: Are there common misunderstandings about how Lucent works?

A common point of clarification is that Lucent (Calcitriol) is the active, ready-to-use hormone form of Vitamin D. Unlike standard Vitamin D supplements, it does not require further activation by the kidneys to be effective, which is a key distinction for patients with kidney issues.


Q: What is the standard regulatory body opinion on Lucent's use?

The regulatory opinion is expressed through the official labeling, which describes the product as indicated for managing specific conditions (e.g., hypocalcemia). The labeling is subject to strict warnings and contraindications for patients with pre-existing conditions like hypercalcemia or Vitamin D toxicity.


Q: Can people who have had specific surgeries still use Lucent?

Lucent is officially indicated for conditions such as post-surgical hypoparathyroidism. Eligibility for use after other specific surgeries is determined by the healthcare provider based on the drug's official contraindications and the patient's current medical status.


Q: Are there any reported long-term research outcomes for Lucent after five years of use?

Yes, research includes long-term observational studies that have tracked patients for over five years. These studies describe findings related to changes in renal function and the calcium phosphate product in specific patient groups over extended periods.

How should Lucent be stored and disposed of?

How to Store and Dispose of Lucent (Calcitriol)

Lucent must be stored according to official regulatory documentation to maintain its stability and effectiveness.


Storage Requirements

Lucent oral capsules require storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat. It must be kept in its original container and the container should remain tightly closed. The injectable solution form is labeled with the specific constraint: Do not freeze. All forms must be stored out of the reach and sight of children.


Disposal Instructions

Unused, expired, or unwanted Lucent must be disposed of in accordance with local pharmaceutical waste requirements. Regulatory information states that the medicine must not be discarded in household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lucent found in:

A-Z Index: